IP Library Granted Patent US 8,916,133
Granted Patent B2
US 8,916,133 · App. 13/801,634 · Granted Dec 23, 2014

Fluorinated 2-amino-4-(benzylamino)phenylcarbamate derivatives

Inventors: Mark E. Duggan (Wellesley, MA); Takeru Furuya (Cambridge, MA); D. Scott Edwards (Bedford, MA); Ajay Purohit (Sudbury, MA)
Assignee: SciFluor Life Sciences, LLC
C07C271/28A61K51/0406C07B59/001C07F15/006C07D213/75C07F5/025
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,916,133
App. No.
13/801,634
Granted
Dec 23, 2014
Kind
B2
Abstract

The invention relates to fluorinated compounds and their use as anti-epileptic, muscle-relaxing, fever-reducing and peripherally analgesically acting medications and as imaging agents. Novel fluorinated 2-amino-4-(benzylamino)phenyl carbamate derivatives of ezogabine and pharmaceutically acceptable salts or solvates thereof and their use are described.

Claims (7)

1. A compound, which is

or a pharmaceutically acceptable salt or solvate thereof.

2. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt or solvate thereof and one or more pharmaceutically acceptable carrier or excipient.

3. A method of treating a subject suffering from or susceptible to conditions ameliorated by KCNQ2/3 potassium channel opening, comprising administering to the subject an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt or solvate thereof.

4. A method of treating or preventing a disease or disorder selected from epilepsy, neurodegenerative disorder, CNS disorder, neurotransmission disorder, cognitive disorder, cancer, inflammatory disease, ophthalmic disease, migraine, bipolar disorder, unipolar depression, anxiety disorder, functional bowel disorder, and tinnitus in a subject in need thereof, comprising administering to the subject an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt or solvate thereof.

5. The method of claim 4 , wherein the disease is epilepsy.

6. A method of producing an analgesic effect in a subject in need thereof, comprising administering to the subject an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt or solvate thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2015
From: SCIFLUOR LIFE SCIENCES, LLC
To: SCIFLUOR LIFE SCIENCES, INC.
Reel/Frame 035960/0496 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2013
From: DUGGAN, MARK E.; FURUYA, TAKERU; EDWARDS, D. SCOTT; PUROHIT, AJAY
To: SCIFLUOR LIFE SCIENCES, LLC
Reel/Frame 030643/0283 →
Continuity (3)
Provisional Application 61640157 · Apr 30, 2012
Provisional Application 61697690 · Sep 6, 2012
Related Publication 20130287686A1 · Oct 31, 2013